# Tenofovir Abacavir Platelet Activation Study

> **NCT02093585** · PHASE4 · COMPLETED · sponsor: **Jan Gerstoft** · enrollment: 43 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** abacavir (600 mg QD)
- **DRUG:** tenofovir (245 mg QD)

## Key facts

- **NCT ID:** NCT02093585
- **Lead sponsor:** Jan Gerstoft
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2016-04
- **Final completion:** 2017-06
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2018-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02093585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02093585, "Tenofovir Abacavir Platelet Activation Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02093585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*